# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Highlighting Improvements In Health-Related Quality Of Life, Bone Length, And Strength In Children With Achondroplasia And Othe...
Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price ...
Truist Securities analyst Joon Lee maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target fr...
Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price targ...
RBC Capital analyst Luca Issi maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price tar...
B of A Securities analyst Geoff Meacham maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price targ...
Stifel analyst Paul Matteis maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $115...
Bernstein analyst William Pickering maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price t...